أرسل هذا في رسالة قصيرة: Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?

  ______    _____              _    _     _____   
 /_   _//  |  ___||   ____    | || | ||  / ____|| 
   | ||    | ||__    |    \\  | || | || / //---`' 
  _| ||    | ||__    | [] ||  | \\_/ || \ \\___   
 /__//     |_____||  |  __//   \____//   \_____|| 
 `--`      `-----`   |_|`-`     `---`     `----`  
                     `-`